Clinical and demographic characteristics of the cohort
| N (%) | |
| Total number of patients | 629 |
| Age (years) | |
| Mean | 63.0 |
| Range | 20.4–94.6 |
| Sex | |
| Female | 284 (45.2) |
| Male | 345 (54.8) |
| ECOG | |
| 0 | 300 (47.7) |
| 1 | 275 (43.7) |
| ≥2 | 54 (8.6) |
| Primary tumor | |
| Melanoma | 268 (42.6) |
| Lung | 128 (20.3) |
| Other | 233 (37.0) |
| Stage | |
| III | 86 (13.7) |
| IV | 543 (86.3) |
| Treatment regimen | |
| Anti-CTLA-4 | 66 (10.5) |
| Anti-PD-1 or Anti-PD-L1 | 415 (66.0) |
| Anti-PD-1+anti-CTLA-4 | 148 (23.5) |
| Treatment line | |
| First | 448 (71.2) |
| Non-first | 181 (28.8) |
| Immunotherapy alone or in combination with other therapy | |
| Alone | 447 (71.2) |
| With other therapy | 182 (28.9) |
| Pretreatment BMI trend | |
| Decreasing | 308 (49.0) |
| Not decreasing | 321 (51.0) |
| Baseline prognostic nutritional index | |
| Low (<45) | 193 (30.7) |
| Normal (≥45) | 436 (69.3) |
| Alive status | |
| Alive | 304 (48.3) |
| Deceased | 325 (51.7) |
| Cancer-specific death | 296 (91.1) |
| Non-cancer-related death | 29 (8.9) |
| Median follow-up (months) | 21.7 |
BMI, body mass index; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; ECOG, Eastern Cooperative Oncology Group; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1.